Companies

Search, filter and compare every US company we cover.

Search companies

Sector

Industry

Size

Today

Profitable Growing

Add filter

Clear all

Revenue growth

Min % Max %

89 companies match

Company	Industry	Market cap	Price	Day change	Revenue	Revenue growth	Operating margin	P/E	5-yr growth	Gross margin	Net margin	Free cash flow	FCF margin	Return on capital	Return on equity	Net debt	Net debt / EBITDA	Dividends + buybacks	Share count change	F-score	Insider buys (90d)	Insider sales (90d)
BeOne Medicines Ltd.ONC	Pharmaceutical Preparations	$568.5B	$377.63	1.2%	$5.3B	40.2%	8.4%	—	76.8%	87.5%	5.4%	$942M	17.6%	46.7%	7.5%	−$3.7B	−6.3x	—	7.8%	8	$0.0M	$0.0M
Alnylam Pharmaceuticals, Inc.ALNY	Pharmaceutical Preparations	$31.0B	$224.03	1.4%	$3.7B	65.2%	13.5%	96.2x	49.8%	81.8%	8.4%	$465M	12.5%	—	73.3%	—	—	—	5.5%	5	$0.0M	$0.0M
INSMED IncINSM	Pharmaceutical Preparations	$20.3B	$93.39	1.8%	$606M	66.7%	−205.6%	—	29.8%	79.7%	−210.5%	−$968M	−159.6%	—	−249.3%	−$859M	—	—	21.3%	4	$0.0M	$0.0M
BridgeBio Pharma, Inc.BBIO	Pharmaceutical Preparations	$13.4B	$68.56	0.6%	$502M	126.3%	−104.2%	—	127.4%	95.8%	−146.0%	−$447M	−89.0%	—	—	$1.4B	—	$48.3M	2.9%	2	$0.0M	$0.0M
Madrigal Pharmaceuticals, Inc.MDGL	Pharmaceutical Preparations	$12.7B	$434.24	4.2%	$958M	432.1%	−31.3%	—	—	—	−30.1%	−$190M	−19.8%	—	−42.5%	−$644M	—	—	5.6%	3	$0.0M	$0.0M
Tg Therapeutics, Inc.TGTX	Pharmaceutical Preparations	$8.5B	$54.17	1.9%	$616M	87.3%	20.0%	19.8x	426.7%	83.7%	72.6%	−$25.0M	−4.1%	16.4%	102.8%	$104M	0.8x	—	0.7%	4	$0.0M	$0.0M
Axsome Therapeutics, Inc.AXSM	Pharmaceutical Preparations	$7.5B	$145.04	7.1%	$638M	65.5%	−26.1%	—	—	—	−28.7%	−$93.9M	−14.7%	—	−252.1%	−$128M	—	—	3.8%	4	$0.0M	$0.0M
Ionis Pharmaceuticals IncIONS	Pharmaceutical Preparations	$7.1B	$42.93	2.2%	$944M	33.8%	−40.4%	—	5.3%	98.3%	−40.4%	−$320M	−33.9%	—	−70.8%	−$865M	—	—	7.0%	3	$0.0M	$0.0M
Kiniksa Pharmaceuticals International, plcKNSA	Pharmaceutical Preparations	$6.3B	$76.73	5.0%	$678M	60.1%	11.4%	84.3x	—	88.5%	8.7%	$136M	20.1%	—	11.7%	—	—	—	10.6%	7	$0.0M	$0.0M
Rhythm Pharmaceuticals, Inc.RYTM	Pharmaceutical Preparations	$6.1B	$89.27	1.8%	$190M	45.8%	−101.2%	—	—	89.7%	−103.6%	−$117M	−61.5%	—	−244.5%	−$281M	—	—	6.5%	6	$0.0M	$0.0M
Ptc Therapeutics, Inc.PTCT	Pharmaceutical Preparations	$5.6B	$60.59	3.9%	$1.7B	114.5%	50.1%	—	35.4%	—	39.4%	$702M	40.6%	—	—	−$1.7B	−1.8x	—	14.9%	6	$0.0M	$0.0M
Mirum Pharmaceuticals, Inc.MIRM	Pharmaceutical Preparations	$5.1B	$80.39	3.3%	$521M	54.7%	−4.2%	—	—	—	−4.5%	$54.9M	10.5%	—	−8.6%	—	—	—	5.6%	4	$0.0M	$0.0M
Travere Therapeutics, Inc.TVTX	Pharmaceutical Preparations	$4.7B	$50.08	4.5%	$491M	110.5%	−12.8%	—	19.9%	97.9%	−5.2%	—	—	—	−29.4%	—	—	—	13.1%	6	$0.0M	$0.0M
Liquidia CorpLQDA	Pharmaceutical Preparations	$4.3B	$42.65	7.5%	$158M	1,031.2%	−32.5%	30.5x	192.5%	—	−43.5%	−$40.0M	−25.3%	—	−111.1%	—	—	—	9.3%	3	$0.0M	$0.0M
Arcutis Biotherapeutics, Inc.ARQT	Pharmaceutical Preparations	$4.2B	$31.20	3.1%	$376M	91.3%	−3.3%	141.8x	—	90.2%	−4.3%	−$6.3M	−1.7%	−12.5%	−9.3%	−$112M	—	—	5.2%	4	$0.0M	$0.0M
AbCellera Biologics Inc.ABCL	Pharmaceutical Preparations	$3.6B	$11.82	4.0%	$75.1M	160.6%	−289.0%	—	−20.3%	—	−194.9%	−$174M	−231.7%	—	−14.5%	—	—	—	1.5%	4	$0.0M	$0.0M
Tango Therapeutics, Inc.TNGX	Pharmaceutical Preparations	$3.5B	$23.34	16.4%	$62.4M	48.3%	−178.4%	—	52.1%	—	−162.9%	−$140M	−224.3%	—	−37.2%	—	—	—	6.4%	3	$0.0M	$0.0M
IDEAYA Biosciences, Inc.IDYA	Pharmaceutical Preparations	$3.2B	$34.71	3.9%	$219M	3,024.4%	−72.8%	—	62.1%	—	−52.0%	−$73.5M	−33.6%	—	−10.9%	—	—	—	8.3%	3	$0.0M	$0.0M
Nurix Therapeutics, Inc.NRIX	Pharmaceutical Preparations	$2.9B	$25.34	0.7%	$84.0M	54.0%	−340.2%	11.0x	36.3%	—	−314.9%	−$263M	−313.7%	—	−49.6%	—	—	—	29.1%	3	$0.0M	$0.0M
Precigen, Inc.PGEN	Pharmaceutical Preparations	$2.6B	$6.19	3.1%	$9.7M	146.7%	−1,141.1%	—	−21.3%	—	−2,588.2%	−$89.8M	−927.6%	−538.0%	−843.6%	−$4.7M	—	—	16.9%	2	$0.0M	$0.0M
Aurinia Pharmaceuticals Inc.AUPH	Pharmaceutical Preparations	$2.3B	$16.86	2.7%	$283M	20.4%	37.1%	7.4x	41.4%	88.5%	101.5%	—	—	—	59.9%	—	—	$98.2M	−5.1%	6	$0.0M	$0.0M
Agios Pharmaceuticals, Inc.AGIO	Pharmaceutical Preparations	$2.2B	$37.00	0.5%	$54.0M	48.0%	−873.9%	—	—	88.3%	−764.0%	−$377M	−698.3%	—	−30.2%	—	—	—	0.1%	2	$0.0M	$0.0M
Zymeworks Inc.ZYME	Pharmaceutical Preparations	$2.1B	$28.22	0.8%	$106M	38.9%	−87.3%	—	22.2%	—	−76.6%	−$34.5M	−32.6%	—	−26.7%	—	—	$41.7M	−0.6%	5	$0.0M	$0.0M
Septerna, Inc.SEPN	Pharmaceutical Preparations	$1.8B	$40.41	1.1%	$46.0M	4,174.5%	−148.6%	—	—	—	−106.4%	$110M	238.7%	—	−12.2%	—	—	—	347.5%	4	$0.0M	$0.0M
Schrodinger, Inc.SDGR	Pharmaceutical Preparations	$1.8B	$23.80	5.3%	$256M	23.3%	−65.2%	—	18.8%	55.7%	−40.4%	$12.5M	4.9%	—	−26.3%	—	—	—	1.1%	4	$0.0M	$0.0M
Palvella Therapeutics, Inc.PVLA	Pharmaceutical Preparations	$1.8B	$125.10	1.0%	$2.6M	303.4%	−1,490.4%	—	−38.5%	—	−1,610.6%	—	—	—	−92.1%	—	—	—	405.5%	2	$0.0M	$0.0M
Xeris Biopharma Holdings, Inc.XERS	Pharmaceutical Preparations	$1.8B	$10.20	6.1%	$292M	43.7%	8.5%	—	70.2%	—	0.2%	—	—	20.2%	—	$109M	4.2x	—	17.7%	7	$0.0M	$0.0M
Zenas BioPharma, Inc.ZBIO	Pharmaceutical Preparations	$1.7B	$26.87	4.8%	$10.0M	100.0%	−3,830.6%	—	—	—	−3,777.4%	−$172M	−1,723.5%	—	−136.2%	−$265M	—	—	238.9%	2	$0.0M	$0.0M
Stoke Therapeutics, Inc.STOK	Pharmaceutical Preparations	$1.7B	$25.04	2.6%	$184M	404.5%	−11.2%	—	—	—	−3.7%	$44.9M	24.4%	—	−2.4%	—	—	—	9.6%	4	$0.0M	$0.0M
Eton Pharmaceuticals, Inc.ETON	Pharmaceutical Preparations	$1.6B	$50.00	0.0%	$80.0M	104.9%	−1.1%	—	359.6%	53.5%	−5.8%	$10.2M	12.7%	−1.7%	−18.2%	$13.4M	4.2x	—	—	4	$0.0M	$0.0M
Ultragenyx Pharmaceutical Inc.RARE	Pharmaceutical Preparations	$1.6B	$15.65	1.9%	$673M	20.2%	−79.5%	—	19.9%	—	−85.4%	−$472M	−70.1%	—	−657.1%	—	—	—	9.0%	4	$0.0M	$0.0M
Anaptysbio, IncANAB	Pharmaceutical Preparations	$1.5B	$48.73	1.3%	$235M	157.0%	96.7%	—	25.6%	—	−5.6%	$19.6M	8.4%	—	−24.5%	—	—	$68.6M	2.3%	4	$0.0M	$0.0M
Damora Therapeutics, Inc.DMRA	Pharmaceutical Preparations	$1.3B	$21.09	2.9%	$1.2M	38.3%	−18,069.6%	2.8x	—	—	−17,981.1%	—	—	—	−163.8%	—	—	—	17.8%	2	$0.0M	$0.0M
Syndax Pharmaceuticals IncSNDX	Pharmaceutical Preparations	$1.2B	$13.40	1.3%	$172M	627.8%	−158.4%	—	157.7%	—	−165.6%	−$323M	−187.5%	−59.2%	−161.8%	$300M	—	—	1.2%	1	$0.0M	$0.0M
Harrow, Inc.HROW	Pharmaceutical Preparations	$1.1B	$28.44	1.0%	$272M	36.4%	11.2%	—	41.0%	75.1%	−1.9%	$43.0M	15.8%	10.5%	−8.4%	$177M	5.5x	—	3.1%	6	$0.0M	$0.0M
Verastem, Inc.VSTM	Pharmaceutical Preparations	$1.0B	$10.04	0.2%	$30.9M	209.1%	−550.3%	—	−19.0%	—	−677.6%	—	—	—	−1,480.2%	—	—	—	94.1%	4	$0.0M	$0.0M
Mannkind CorpMNKD	Pharmaceutical Preparations	$986M	$3.19	0.3%	$349M	22.2%	11.1%	—	39.9%	92.3%	1.7%	$13.7M	3.9%	29.3%	—	$183M	3.6x	—	10.7%	3	$0.0M	$0.0M
Rigel Pharmaceuticals IncRIGL	Pharmaceutical Preparations	$942M	$48.13	1.5%	$294M	64.1%	42.6%	2.8x	22.1%	93.3%	124.7%	—	—	43.4%	185.9%	−$102M	−0.8x	—	6.5%	6	$0.0M	$0.0M
Kura Oncology, Inc.KURA	Pharmaceutical Preparations	$854M	$9.61	2.5%	$67.5M	25.2%	−449.9%	—	—	—	−412.9%	−$70.7M	−104.8%	—	−94.8%	−$658M	—	—	1.8%	2	$0.0M	$0.0M
Pharming Group N.V.PHAR	Pharmaceutical Preparations	$836M	$11.20	5.0%	$376M	26.6%	6.9%	—	12.1%	87.9%	0.8%	$54.0M	14.3%	—	1.1%	—	—	—	−4.9%	6	$0.0M	$0.0M
Arbutus Biopharma CorpABUS	Pharmaceutical Preparations	$829M	$4.20	0.2%	$14.1M	128.2%	−271.0%	5.3x	15.3%	—	−237.9%	−$39.6M	−281.5%	—	−38.5%	−$91.5M	—	—	3.2%	3	$0.0M	$0.0M
Ardelyx, Inc.ARDX	Pharmaceutical Preparations	$764M	$3.08	3.8%	$407M	22.1%	−10.1%	—	121.9%	90.3%	−15.1%	−$44.0M	−10.8%	−30.8%	−36.2%	−$61.9M	—	—	2.5%	3	$0.0M	$0.0M
CorMedix Inc.CRMD	Pharmaceutical Preparations	$726M	$7.85	3.1%	$312M	617.0%	48.2%	3.6x	319.8%	88.5%	52.3%	$173M	55.4%	—	66.6%	—	—	—	36.3%	5	$0.0M	$0.0M
Lexicon Pharmaceuticals, Inc.LXRX	Pharmaceutical Preparations	$621M	$1.42	4.7%	$49.8M	60.2%	−98.2%	—	15.7%	99.4%	−101.1%	−$67.9M	−136.2%	−59.2%	−39.7%	−$42.2M	—	—	13.4%	4	$0.0M	$0.0M
Zevra Therapeutics, Inc.ZVRA	Pharmaceutical Preparations	$602M	$9.81	5.0%	$106M	350.9%	−59.1%	10.4x	51.6%	—	78.2%	−$2.4M	−2.3%	−236.3%	85.7%	−$129M	—	—	23.8%	5	$0.0M	$0.0M
Phathom Pharmaceuticals, Inc.PHAT	Pharmaceutical Preparations	$481M	$5.74	18.1%	$175M	216.9%	−91.4%	—	—	87.1%	−126.3%	−$167M	−95.4%	—	—	$79.1M	—	—	15.4%	4	$0.0M	$0.0M
Altimmune, Inc.ALT	Pharmaceutical Preparations	$393M	$2.12	2.3%	$0.0M	105.0%	−230,461.0%	—	−65.3%	—	−214,861.0%	−$67.5M	−164,746.3%	—	−50.6%	−$239M	—	—	24.1%	4	$0.0M	$0.0M
Opus Genetics, Inc.IRD	Pharmaceutical Preparations	$387M	$3.47	9.2%	$14.2M	29.1%	−271.9%	—	—	—	−349.3%	—	—	—	−449.4%	−$44.0M	—	—	132.9%	3	$0.0M	$0.0M
Assembly Biosciences, Inc.ASMB	Pharmaceutical Preparations	$374M	$19.84	2.2%	$72.3M	153.5%	−16.8%	16.4x	−1.8%	—	−8.5%	−$41.2M	−56.9%	—	−5.1%	—	—	—	86.7%	3	$0.0M	$0.0M
Prelude Therapeutics IncPRLD	Pharmaceutical Preparations	$357M	$3.63	0.8%	$12.1M	73.4%	−861.3%	—	—	—	−819.6%	−$56.4M	−464.3%	—	−99.5%	—	—	—	1.5%	3	$0.0M	$0.0M

What do these columns mean?

Market cap: Last close times the latest diluted share count, so it is approximate.
Price: Closing share price on the last trading day.
Day change: Change in the closing price against the previous trading day's close.
Revenue: Total sales reported in the income statement.
Revenue growth: Change in revenue against the year (or quarter) a year earlier.
Operating margin: Operating income as a share of revenue.
P/E: Last close divided by diluted earnings per share over the last four quarters.
5-yr growth: Revenue growth a year, compounded over the last five years.
Gross margin: Gross profit as a share of revenue.
Net margin: Net income as a share of revenue.
Free cash flow: Cash from operations minus capital spending.
FCF margin: Free cash flow as a share of revenue.
Return on capital: After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on equity: Net income as a share of average shareholders' equity.
Net debt: Debt and finance leases minus cash and short-term investments. Negative means net cash.
Net debt / EBITDA: Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
Dividends + buybacks: Cash returned to shareholders through dividends and share repurchases.
Share count change: Change in the diluted share count. Negative means buybacks shrank it.
F-score: Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
Industry: The industry the company reports under, from its SEC filing code. Click it to see its peers.
Colours and dashes: Green is up or growing, red is down or shrinking. — means no data, or a P/E that is not meaningful (losses, or above 200).
Units: M = millions, B = billions, T = trillions, in USD. Fundamentals use the latest fiscal year. Use “Edit columns” to show more figures, hide some or change their order.